Ovarian Cancer

The treatment of platinum-resistant ovarian cancer is challenging, with limited therapeutic options. Antibody-drug conjugates as single agents or in combinations are showing promise for these patients.

Erika P. Hamilton, MD, discusses unmet needs in treatment options for platinum-resistant ovarian cancer due to the challenges of screening, and what treatment options may become viable in the future.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the findings from a study of rebastinib plus paclitaxel and unmet needs in the ovarian cancer setting.

Mirvetuximab soravtansine is an FRα-targeting antibody-drug conjugate, which in a phase 1/2 study demonstrated significant activity in select patients with ovarian cancer.

PARP inhibitors are a common treatment for ovarian cancer, but mechanisms of resistance have yet to be fully understood.

An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.

Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.

A key opinion leader shares data from a phase III, ARIEL3, clinical trial on rucaparib maintenance treatment for ovarian cancer.

Dr. Lyndsay Willmott discusses the front-line therapy options for ovarian cancer and the factors considered in choosing maintenance therapies.

An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.

In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.

In an interview with Targeted Oncology, John Diaz, MD, discussed the ovarian cancer treatment paradigm and the promise of STRO-002 for an important ovarian cancer subgroup.

In an interview with Targeted Oncology, Rodney P. Rocconi, MD, FACOG, discussed the analysis of the homologous recombination proficient patients with advanced-stage ovarian cancer treated in the phase 2 VITAL study as well as a biomarker analysis.

Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.

Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.

In an interview with Targeted Oncology™, Stephanie L. Wethington, MD, MSc, discussed the modern treatment of high-grade serous ovarian cancer and the study of olaparib plus ceralasertib as a strategy for overcoming resistance to PARP inhibition.

The FDA has granted a fast track designation to the folate receptor alpha-targeting antibody-drug conjugate, STRO-002, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

In an interview with Targeted Oncology™, David O’Malley, MD, discussed the results from an arm of the phase 2 study of 5 mirvetuximab-containing regimens that were evaluated for the treatment of patients with FRα-positive ovarian cancer.

Outcomes in patients with advanced recurrent ovarian cancer treated with the novel immunotherapeutic vaccine maveropepimut-S appeared encouraging, according to topline results from the DeCidE1 clinical trial.

In an interview with Targeted Oncology™ following a presentation of the study protocol at the 2021 American Society of Clinical Oncology Annual Meeting, Susana K. Banerjee, PhD, explained the progress of ENGOT-ov60/GOG3052/RAMP 201 in detail.

In an interview with Targeted Oncology, Ainhoa Madariaga, MD, explained the similarities between the primary and exploratory analyses of adavosertib and gemcitabine in patients with ovarian cancer as it relates to toxicity.

Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer.

In an interview with Targeted Oncology, Rachel N. Grisham, MD, discussed binimetinib’s effect on patients with ovarian cancer harboring a KRAS mutation. 

David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.